Prediction of high and low disease activity in early MS patients using multiple kernel learning identifies importance of lateral ventricle intensity

Claudia Chien, Moritz Seiler, Fabian Eitel, Tanja Schmitz-Hübsch, Friedemann Paul and Kerstin Ritter

Abstract

Background: Lack of easy-to-interpret disease activity prediction methods in early MS can lead to worse patient prognosis.

Objectives: Using machine learning (multiple kernel learning – MKL) models, we assessed the prognostic value of various clinical and MRI measures for disease activity.

Methods: Early MS patients (n = 148) with at least two associated clinical and MRI visits were investigated. T2-weighted MRIs were cropped to contain mainly the lateral ventricles (LV). High disease activity was defined as surpassing NEDA-3 Criteria more than once per year. Clinical demographic, MRI-extracted image-derived phenotypes (IDP), and MRI data were used as inputs for separate kernels to predict future disease activity with MKL. Model performance was compared using bootstrapped effect size analysis of mean differences.

Results: A total of 681 visits were included, where 81 (55%) patients had high disease activity in a combined end point measure using all follow-up visits. MKL model discrimination performance was moderate (AUC ≥ 0.62); however, modelling with combined clinical and cropped LV kernels gave the highest prediction performance (AUC = 0.70).

Conclusions: MRIs contain valuable information on future disease activity, especially in and around the LV. MKL techniques for combining different data types can be used for the prediction of disease activity in a relatively small MS cohort.

Keywords: Relapsing/remitting, MRI, disease activity prediction, multiple kernel learning, lateral ventricles, machine learning

Date received: 17 December 2021; accepted 10 June 2022
load or brain volumetrics that are reliant on many intensive preprocessing and partially manual steps, using raw-MRIs centred and cropped at the LV-CP region could result in better modelling by ML algorithms. In this study, we aim to predict the level of disease activity in early relapsing-remitting MS (RRMS) patients using MKL, allowing for the combination of clinical, image-derived, and raw-MRI data. We hypothesise that clinical data, MRI-extracted features, and raw-MRIs cropped at the LV-CP region will yield clinically relevant models for the prediction of future disease activity using MKL models.

Methods

Study population

Patient data were acquired from our ongoing, longitudinal observational early MS cohort (Berlin of Clinically Isolated Syndrome (CIS) cohort: ClinicalTrials.gov Identifier: NCT01371071, start date: January 2011). The study includes patients over the age of 18, with a diagnosis CIS or RRMS according to the McDonald 2017 diagnostic criteria. We screened 168 patients for the availability of at least two MRI scans performed within three months of clinical assessments. Criteria were met for 148 patients with CIS (N=39) or early RRMS (N=109). This study was approved by the local ethics committee (EA1/182/10) and conducted in accordance with the current applicable version of the Declaration of Helsinki and German law. All participants provided written informed consent. All relevant patient baseline clinical and MRI-derived information are shown in Table 1.

MRI acquisition

This study utilised longitudinally acquired MRIs with a protocol that included a 3D magnetization prepared rapid acquisition gradient echo (MPRAGE) sequence (1 mm isotropic resolution, TR = 1900 ms, TE = 3.03 ms, TI = 900 ms), and a 3D fluid-attenuated inversion recovery (FLAIR) sequence (1 mm isotropic resolution, TR = 6000 ms, TE = 388 ms, TI = 2100 ms) using a 3 Tesla Tim Trio MRI (Siemens Medical Systems, Erlangen, Germany).

MRI preprocessing

Preprocessing included white and grey matter brain masking for brain extraction, N4-bias field correction and linear, rigid body registration of FLAIR images to MPRAGE images. MPRAGE and FLAIR scans were longitudinally co-registered as described in Cooper et al. Cerebral Gd- and T2-hyperintense lesions were segmented manually and saved as binary masks using ITK-SNAP (www.itksnap.org) by two expert MRI technicians (greater than 10 years of experience). Longitudinally co-registered MPRAGEs were lesion-filled (https://fsl.fmrib.ox.ac.uk/fsl/fslwiki/lesion_filling) and used for whole brain, white and grey matter and CSF normalised volume extraction. Each lesion from lesion masks were thresholded to contain at least 15 voxels to reduce the chance of including very small non-specific lesions and/or hyperintense-artefacts for lesion count and volume extraction (https://fsl.fmrib.ox.ac.uk/fsl/fslwiki/Fslutils). Brain-extracted FLAIRs were centred at the LV-CP and cropped by reducing the dimensions to 60 × 54 × 2 mm, using an inhouse Python script. This size was chosen, as it effectively reduces the dimensionality of the image for ML processing and contains the most MRI slices with the LV and CP in view.

NEDA-3 criteria

We used a combined endpoint measure to define no evidence of disease activity (NEDA). NEDA-3 can be defined as a lack of clinical relapses, a lack of disease progression measured by the expanded disability status scale (EDSS) and an absence of new brain lesions (new/enlarged T2-hyperintense and/or Gd-enhancing lesion) in an MRI after the baseline visit. In the current study, NEDA-3 status is calculated between consecutive visits and not from the baseline MRI visit. Thus, patients may fail NEDA-3 at each follow-up session, indicating an increase in disease activity.

To maintain NEDA-3 status at each time point, a patient must have:

1. No new occurrence of relapses
2. No disability progression in terms of increases in EDSS scores. A binary variable for disability progression is introduced based on different thresholds depending on the EDSS score at the previous time point.
3. No increases in the counts or volumes of T2-lesions and Gd-enhancing lesions from brain MRIs.

The above criteria were used to determine the NEDA-3 status at each follow-up visit. Since Gd MRIs were not collected for all patients at every time point, this information is only used for provided cases and ignored otherwise.
Table 1. CIS and early RRMS cohort baseline characteristics.

<table>
<thead>
<tr>
<th></th>
<th>High disease activity ($n=81$)</th>
<th>Low disease activity ($n=67$)</th>
<th>All patients ($n=148$)</th>
<th>Statistics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years) [mean± SD]</td>
<td>32.8± 8.2</td>
<td>34.4± 9.4</td>
<td>33.5± 8.8</td>
<td>NA</td>
</tr>
<tr>
<td>Disease Duration at Baseline [months] [median (range)]</td>
<td>4.7 (0–28)</td>
<td>5 (1–35)</td>
<td>4 (0–35)</td>
<td>$t=-1.802, p=0.962$</td>
</tr>
<tr>
<td>EDSS Score at Baseline [median (range)]</td>
<td>1.5 (0–4)</td>
<td>1.5 (0–4)</td>
<td>1.5 (0–4)</td>
<td>$t=-1.174, p=0.879$</td>
</tr>
<tr>
<td>Follow-up visits (N) [median (range)]</td>
<td>4 (2–9)</td>
<td>5 (2–10)</td>
<td>4 (2–10)</td>
<td>$t=-2.313, p=0.989$</td>
</tr>
<tr>
<td>MS Therapies (N) [%]</td>
<td>Dimethylfumarate: 9 (11)</td>
<td>Dimethylfumarate: 3 (5)</td>
<td>Dimethylfumarate: 12 (8)</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td>Glatirameracetat: 15 (19)</td>
<td>Glatirameracetat: 10 (15)</td>
<td>Glatirameracetat: 25 (17)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>NA: 47 (58)</td>
<td>NA: 49 (73)</td>
<td>NA: 96 (65)</td>
<td></td>
</tr>
<tr>
<td>Disease Activity based on NEDA-3 Status at each time point (N) [high:low (%)]</td>
<td>NA</td>
<td>NA</td>
<td>81:67 (55:45)</td>
<td>$\chi^2=1.324, p=0.249$</td>
</tr>
<tr>
<td>Brain T2-hyperintense lesion count (N) [median (range)]</td>
<td>11 (1–83)</td>
<td>9 (0–217)</td>
<td>10 (0–217)</td>
<td>$t=0.115, p=0.454$</td>
</tr>
</tbody>
</table>

Chi-squared test statistics were calculated only using data from the all patients column, not within each disease activity group. Welch two-sample t-tests were performed only between high and low disease activity groups. Bolded text indicates statistical significance ($p<0.05$). It should be noted that for MS Therapies, NA denotes no treatment, since most patients at baseline were originally included into the observational study as CIS patients.

CIS: clinically isolated syndrome; RRMS: relapsing-remitting MS; EDSS: expanded disability status scale; NEDA-3: no evidence of disease activity; SD: standard deviation.
Future high and low disease activity
A binary measure of low (0) or high (1) disease activity for each patient was calculated. First, NEDA-3 status was evaluated per patient session, then all instances where NEDA-3 was surpassed were summed for each patient. The number of instances was divided by the total time in years from baseline to last follow-up visit using this formula:

\[
\text{Annualised NEDA-3} = \frac{\text{Total NEDA-3 surpassing events per patient}}{\text{Total follow-up time in years}}
\]

Values greater than 1 may occur, depending on the frequency of follow-up visits. For example, one patient had two visits 0.126 years apart, where NEDA-3 was surpassed in the second visit. This would give an annualised NEDA-3 of \(1/0.126 = 7.93\). Thus, this calculation is able to account for the temporal aspect of the prediction, as well as adjusting for differences in follow-up times and visits for each patient. The annualised NEDA-3 distribution of all patients showed centrality around 1 surpassing event per year (Figure 1). High disease activity was counted as \(\geq 1\) surpassing event per year, and low disease activity was designated as \(<1\) surpassing event per year.

Input features for the ML model
The prediction of low and high disease activity was based on the following sets of baseline features:

1. Clinical-related (Clin) – four variables: age, disease duration from first manifestation in months, EDSS score, sex
2. Image-derived phenotypes (IDP) – five variables: T2-hyperintense brain lesion count, total brain, brain grey, white matter and CSF normalised volumes
3. Raw-MRIs (MRI) – 6480 variables (intensity value per voxel): flattened one-dimensional vector from FLAIR images centred on the CP and cropped around the LV

Each set of features (Clin, IDP, and MRI) were standardised using sklearn StandardScaler\(^{19}\) and input into separate radial basis function (RBF) kernels for fitting to the ML algorithm.

Mklaren model
We used the Mklaren (Multiple kernel learning with least-angle regression) algorithm, which performs simultaneous low-rank approximation of MKL with least-angle regression to find the best combination of RBF kernel matrix columns to use for training and prediction (6). We optimised all available hyperparameters in this algorithm (Supplemental Table 1).

Different combinations of RBF kernels were used to create the following Mklaren models (Figure 2):

1. Only Clin
2. Only IDP
3. Only MRI
4. Clin and IDP
5. Clin and MRI
6. IDP and MRI
7. Clin, IDP and MRI

Interchangeably using IDP and MRI features allowed for an indirect comparison of whether non-extracted MRI measures (MRI) could be used in predictive models as well as preprocessed and MRI-extracted measures.

Statistical analysis
Chi-squared and Welch two-sample t-tests were performed to test for significant differences between cohort demographics (Table 1). Ten repetitions of five-fold nested cross-validation were performed for each Mklaren model. Outer and inner loops were split using stratified K-folds\(^{19}\) to give balanced sex and outcome measure grouping in training and validation/test sets. The inner loops were used to select models with hyperparameter sets that gave the Mklaren model with the highest validation receiver operating characteristic area under the curve (AUC) and lowest root mean square error. Since the Mklaren algorithm is a regression model, and our task is a classification, we used the validation AUC from each inner loop selected model to calculate an optimal value (using an in-house python script) that was applied to the regression output for binarising into high and low disease activity classes. In addition, we thresholded the selection of the top AUCs from each inner loop to be above 0.55, to reduce the possibility of selecting models which learned the classification based on chance (Supplemental Statistical Analysis Text). The identified sets of hyperparameters per inner loop were then used on the outer loop to obtain performance measures (test AUC, balanced accuracy, sensitivity, specificity). The mean performance measures per outer loop were then calculated (Figure 2). Performance measures were calculated using standard sklearn metrics tools.\(^{19}\) To compare the AUC, balanced accuracy, sensitivity, and specificity of each different Mklaren model, mean differences between each model (Mklaren models ii – vii) against the model using only clinical data (Mklaren...
model i) were calculated using 5000 bootstrap resamples in R.\textsuperscript{20} Kaplan–Meier estimation analysis\textsuperscript{21} was used to evaluate whether baseline low (< mean of all mean intensity measures in the cohort) versus high mean intensities in the cropped MRIs have different risk of failing NEDA-3 Criteria. To investigate how mean intensity measures in the cropped MRIs compare between high and low disease activity patients, a Welch’s two-sample t-test was used. Statistical significance was set to \( p < 0.05 \) for all tests. All statistics on demographics, Kaplan–Meier, performance measures, and t-tests were performed using R version 4.1.0 (https://www.r-project.org/).

Data availability

Persons interested in obtaining access to the data should contact Friedemann Paul (friedemann.paul@charite.de).

Results

Cohort demographics

As expected, the cohort included larger proportions of females and RRMS patients compared to CIS (Table 1). To account for sex, we stratified our training, validation and test sets for sex and outcome measure to reduce bias in model fitting and identification of sex as a predictor. In terms of diagnosis, we did not subset the group of CIS patients since only 18 patients (12\%) in their last visit remained CIS, and these patients represent normal variation in an early MS cohort.

High versus low disease activity patients

We visually inspected the 3D cropped raw FLAIR LV region, which was imported as arrays of intensity values, where the mean was calculated using all imported image arrays of high and low disease activity patients at baseline, respectively (Figure 3). An average increase in image intensity was observed in the patients with high disease activity (Figure 3C), confirming that this region could be of interest for MKL. Mean lesion masks in the same cropped regions from each group were assessed by importing as arrays, giving Figure 3D to F.

MKL experiments

Table 2 shows the performance measures of each model used to predict high versus low disease activity in this early RRMS cohort. The effect sizes of the mean differences between performance measures of each model (ii – vii) from model i (only clinical tabular data) are included.

It can be seen from the effect size analysis, the model fit with both tabular clinical and cropped raw-MRI of
the LV (Clin + MRI) gave the highest mean difference against models using only tabular clinical data (Supplemental Figure 1). Using these kernels in

the Mklaren model gave the highest mean performance measures for predicting high disease activity in CIS and RRMS patients (AUC = 0.70, balanced

EDSS: expanded disability status scale; CSF: cerebral spinal fluid; 1D: 1-dimensional; AUC: area under the curve; Clin: clinical data; IDP: image-derived phenotypes; MRI: cropped MRIs at the lateral ventricles; RBF: radial basis function; MKL: multiple kernel learning.

Figure 2. Outline of experimental design for MKL. (1) Types of different data used as inputs for (2) RBF kernels, which were then used for (3) fitting to training data and MKL. Kernels that are highly related to target outcomes are approximated with better accuracies. Combined approximations are used to (4) predict low vs. high disease activity in the validation and test set, and (5) calculate and evaluate performance measures for the Mklaren models.
accuracy = 0.63, and specificity = 0.73). This model did not have the highest sensitivity in the tested models. This would suggest that the model with clinical and raw MRI data is not able to predict true positives of high disease activity as well as models using IDP data combinations, however, was better at distinguishing true negatives.

**Cropped T2-weighted raw-MRIs around the lateral ventricles**

Baseline mean intensities of the cropped MRI region, stratified by low (patient baseline mean intensity < mean of all baseline mean intensities) and high values, were evaluated to see whether intensity groupings could distinguish between a higher risk of failing the NEDA-3 Criteria from baseline (Supplemental Figure 2). There was no significant difference in risk between the LV MRI intensity groups. However, it can be seen that in our cohort 50% of patients risk failing NEDA-3 Criteria around six months after baseline. We investigated further if the baseline mean intensities from the cropped MRIs around the LV showed differences between low and high disease activity patient groups using a Welch’s two-sample t-test (Figure 4).

Figure 4B shows the hyperintense CP of a high disease activity patient with the highest mean image intensity shown in Figure 4A. Although N4-bias correction (14) of the FLAIR MRIs was performed during the MRI preprocessing stage, there are higher intensities from this LV region in patients with high disease activity ($t = -64.1, p < 2.2 \times 10^{-16}$).

**Discussion**

Our study showed that the MKL MkIaren method can aid in the prediction of future disease activity in CIS and early RRMS patients. In addition, we trained MKL models using raw, cropped T2-FLAIR MRIs, allowing for the use of minimally preprocessed, clinically relevant MRIs in an ML classification task. RBF kernels combining baseline clinical (age, sex, disease duration, EDSS score) with cropped MRIs at the LV region gave the highest predictive performance measures for high vs. low disease activity. We also evaluated the mean intensity measures of the cropped LV regions, centred on the CP, which showed higher mean baseline MRI intensities in patients classified with high disease activity, than patients classified with low disease activity.
Table 2. Performance measures and effect sizes of Mklaren models used for prediction of high versus low disease activity.

<table>
<thead>
<tr>
<th>Performance measures</th>
<th>Tabular clinical data kernel</th>
<th>Tabular IDP kernel</th>
<th>MRI kernel</th>
<th>Clinical + IDP kernels</th>
<th>Clinical + MRI kernels</th>
<th>IDP + MRI kernels</th>
<th>Clinical + IDP + MRI (all kernels)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean AUC ± SD</td>
<td>0.62 ± 0.06</td>
<td>0.65 ± 0.06</td>
<td>0.70 ± 0.07</td>
<td>0.66 ± 0.04</td>
<td>0.70 ± 0.05</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(Effect-size [95% CI])</td>
<td>(−0.005 to 0.016)</td>
<td>(0.028 to 0.033)</td>
<td>(0.081 to 0.111)</td>
<td>(0.017 to 0.059)</td>
<td>(0.073 to 0.094)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean Balanced Accuracy ±SD</td>
<td>0.55 ± 0.06</td>
<td>0.58 ± 0.07</td>
<td>0.63 ± 0.07</td>
<td>0.58 ± 0.07</td>
<td>0.61 ± 0.06</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(Effect-size [95% CI])</td>
<td>(−0.036 to 0.018)</td>
<td>(0.038 to 0.028)</td>
<td>(0.084 to 0.111)</td>
<td>(0.032 to 0.055)</td>
<td>(0.065 to 0.089)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean Sensitivity ±SD</td>
<td>0.45 ± 0.17</td>
<td>0.61 ± 0.17</td>
<td>0.60 ± 0.29</td>
<td>0.57 ± 0.23</td>
<td>0.57 ± 0.23</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(Effect-size [95% CI])</td>
<td>(−0.132 to −0.087)</td>
<td>(0.123 to 0.258)</td>
<td>(0.076 to 0.153)</td>
<td>(0.122 to 0.238)</td>
<td>(0.122 to 0.238)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean Specificity ±SD</td>
<td>0.64 ± 0.04</td>
<td>0.56 ± 0.20</td>
<td>0.73 ± 0.17</td>
<td>0.65 ± 0.21</td>
<td>0.65 ± 0.21</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(Effect-size [95% CI])</td>
<td>(−0.245 to −0.08)</td>
<td>(−0.124 to 0.258)</td>
<td>(0.092 to −0.089)</td>
<td>(0.099 to −0.11)</td>
<td>(0.099 to −0.11)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Bolded text indicates highest effect sizes of mean differences in performance measures in comparison to using kernels input with only tabular clinical data.

AUC: area under the curve; SD: standard deviation; CI: confidence interval; IDP: image-derived phenotypes; MRI: cropped MRIs at the lateral ventricles.
We did not see the utility of tabular clinical data alone in our Mklaren models for predicting future disease activity; however, it did give models with the highest specificity compared to others using single data types. The Mklaren models including IDP had slightly higher sensitivity, suggesting true positive (or high disease activity) are better identified with the inclusion of MRI-extracted information, which is in-line with other MS ML studies. Some other large studies were able to discern the probability of disease progression to secondary progressive MS using ML methods solely with baseline EDSS and age. Brain age in MS has become an important line of research, and age is associated with brain atrophy rates, thus it is important to continue to include age in MRI studies. Using an MKL approach with clinical tabular and IDP data may be useful in classification tasks within smaller cohorts.

Typical IDP data for ML prediction tasks involve brain-extracted and advanced MRI-extracted measures, such as connectivity measures based on lesions in the white matter. This is not only time-consuming to pre-process and post-process the MRI data, there is a need to reduce dimensionality for ML modelling. In our study, the Mklaren MKL algorithm automatically combines the data by fitting RBF kernels to the task using simultaneous low-rank approximation with least angle regression. This reduces the computational complexity of the model allowing for large amounts of observations to be analysed, such as that from raw-MRIs, where the removal of kernel columns that do not aid in the prediction task is also performed. Since kernels are based on each different type of data, this approach is flexible for use in different cohorts with different types of observations. As discussed in Tozlu et al., advanced MRI techniques until now are mainly for research purposes and thus, we need to shift towards a more clinically applicable tool, such as one able to read raw MRI data, for patient evaluation.

The LV intensities from FLAIR MRIs are a region of high interest in evaluating future disease activity in MS. We observed in patients classified as having high disease activity, based on the annualised NEDA-3 score, significantly higher mean intensities in the LV-CP compared to patients with low disease activity. Our visual evaluation of the LV region also showed that there may be a higher incidence of lesions/T2-hyperintensities in the splenium of the corpus callosum in high disease activity patients, consistent with a previous study that found higher disability scores in patients with white matter damage in the splenium. Baseline mean intensity measures of the LV region did not show a different risk of failing NEDA-3 Criteria in a Kaplan–Meier analysis. However, 50% of the entire patient cohort risked evidence of disease activity six months after baseline, highlighting the need for early treatment to avoid further MS-related disease activity. We posit that for better prediction of future disease activity using MKL and information from the LV, patients may decide for disease-modifying therapy prior to their next relapse or MRI finding. The CP in the LV is pertinent to investigate since increased CP volume has been shown to be associated with inflammation in MS patients, although, studies have found LV and CP enlargement from normal aging.
study, we included LV intensities as a feature because a recent study showed increased Gd-enhancement of the LV-CP in MS patients. Meanwhile, another study found increased intensity in FLAIR MRI from higher protein concentration detection usually suppressed in the CSF at normal concentrations. Importantly, it has been found that the pattern of neurdregeneration in MS is associated with the load of inflammatory infiltrates in the CSF, such as chemokines that are produced by the CP and then affecting the LV regions. Thus, along with previous findings that the ventricular volume in early RRMS patients transiently fluctuates, our findings using raw-MRI data even without contrast enhancement, support observations that disease activity may be related to changes in the CP and LV. Our results could lead to a more easily accessible clinical tool, whereby patient raw MRIs (i.e. T2-FLAIR) are input directly from the scanner into an automated pipeline that evaluates the risk of a patient having high disease activity in the future.

One limitation of our study was the small cohort size for an ML prediction task. For small patient cohorts, not only could the dataset have low statistical power, the variability in the data splitting for ML training, as well as the choice of features, can lead to unstable performance results. We decreased bias in the training, validation, and test sets of the data by stratifying splitting based on both the outcome variable (low and high disease activity groupings) and sex, which is often an important confounder of MRI brain data. Since the Mklaren algorithm allows for flexibility in using large numbers of observations for prediction, it was also a well-suited choice for our small dataset. Although other types of ML methods such as ensemble learning could also be of value, as they are not limited to just one type of algorithm or model per class of data, this advanced modelling would require much more post-processing of the models and data. Therefore, we believe using our stratification strategy with MKL for the prediction of disease activity in MS was a sound choice.

Another limitation of our study includes the difference in the number of follow-up visits between patients. To account for this, we calculated an annualised NEDA-3 score, which allowed us to evaluate at each visit, whether a patient surpassed the NEDA-3 Criteria. This was further binarised into patients with high activity (annualised NEDA-3 score ≥1) and low activity based on the overall distribution of the score in our cohort. Thus, we could still test for future disease activity using all the available follow-up visit data, which was successfully predicted with moderate performance using tabular clinical and raw-MRI data.

Conclusion
MKL can be applied to clinical, MRI-extracted, and raw T2-weighted MRI data for the prediction of future disease activity in CIS and early RRMS patients. MKL with individual kernels for different types of data may allow for a better and more personalised assessment of disease course. Automatically analysing raw-MRI data, especially in the LV/CP region could enable clinicians and patients to make treatment decisions based on probable future disease activity. These methods, including evaluation of feature importance, and brain regions warrant further investigation in larger MS studies.

Acknowledgements
The authors would like to thank all patients who volunteered for this observational study and the study nurses, MRI technicians (C. Kraut and S. Pikol), the Berlin Center for Advanced Neuroimaging, and residents who aided in collecting the clinical data and the NeuroCure Clinical Research Center for infrastructure and regulatory support.

Declaration of conflicting interests
The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: C.C. has received speaking honoraria from Bayer and funding for research by Novartis, unrelated to this study. T.S.H has received speaker honoraria from Bayer, travel grant from Celgene, and funding for research by Roche and Celgene, unrelated to this study. F.P. receives honoraria for lecturing, and travel expenses for attending meetings from Guthy Jackson Foundation, Bayer, travel grant from Celgene, and funding for research by Roche and Celgene. His research is funded by the German Ministry for Education and Research (BMBF), Deutsche Forschungsgemeinschaft (DFG), Einstein Foundation, Guthy Jackson Charitable Foundation, EU FP7 Framework Program, Biogen, Genzyme, Merck Serono, Novartis, Alexion, Viela Bio, Roche, UCB, Mitsubishi Tanabe and Celgene. His funding is supported by the Deutsche Multiple Sklerose Gesellschaft (DMSG), Deutsche Forschungsgemeinschaft (DFG grant number 389563835), Fondation Eugène Devic EDMUS contre la Sclérose en Plaques & Observatoire Français de la Sclérose en Plaques (grant name DEEP MS), and the German Research Foundation. We acknowledge financial support...
from the Open Access Publication Fund of Charité – Universitätsmedizin Berlin and the German Research Foundation (DFG).

**ORCID iD**
Claudia Chien https://orcid.org/0000-0001-8280-9513

**Supplemental material**
Supplemental material for this article is available online.

**References**


